AstraZeneca Breaks Ground on $475M Small Molecule Drug Manufacturing Plant in Wuxi, China

On May 8, AstraZeneca's new small molecule drug factory in Wuxi officially broke ground, with a total investment of $4.75 billion (approximately 3.441 billion yuan).

The new factory, covering an area of approximately 30,000 square meters, will be equipped with two sets of advanced continuous tablet manufacturing equipment and seven sustainable pharmaceutical packaging production lines. It will mainly produce innovative cardiovascular drugs from AstraZeneca's R&D pipeline and is expected to commence operations in the fourth quarter of 2028.

After the new factory is completed, it will further increase the production capacity of the Wuxi production and supply base.

Since its operation in 2001, the Wuxi production and supply base has become one of the important pillars of AstraZeneca's global supply chain, supplying more than 20 products to over 70 markets worldwide.

Earlier, the first phase (main building) of AstraZeneca's Qingdao inhalation aerosol production and supply base had just been completed. The total investment in the base project is 750 million US dollars, covering an area of 80 mu. After production begins, it will become an intelligent, high-capacity, and comprehensive inhalation aerosol production and supply base, with an expected annual output of 54 million respiratory drugs, which will be supplied to the Chinese market.